Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer

Published:2010-09 Issue:8 Volume:21 Page:749-758
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Oostendorp Linda J.M.,Stalmeier Peep F.,Pasker-de Jong Pieternel C.,Van der Graaf Winette T.,Ottevanger Petronella B.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference48 articles.

1. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005

2. Randomized phase II study of irinotecan plus mitomycin C versus oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer;Scheithauer;Cancer Invest,2002

3. Optimizing the use of irinotecan in colorectal cancer;Cunningham;Oncologist,2001

4. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;Cutsem van;Ann Oncol,2009

5. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study;Cutsem van;Br J Cancer,2005

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases;British Journal of Surgery;2023-07-19

2. Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges;Frontiers in Oncology;2021-03-16

3. The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma;Cancer Immunology, Immunotherapy;2020-08-25

4.

Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy

;International Journal of Nanomedicine;2019-07

5. Hydrophobized SN38 to redox-hypersensitive nanorods for cancer therapy;Journal of Materials Chemistry B;2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3